Bracco Diagnostics Inc. Announces Update on Product Portfolio

Bracco Diagnostics Inc. Announces Update on Product Portfolio

Strategic decisions enable Bracco to serve better the needs of healthcare providers and patients with its enhanced pipeline offering.

 

Bracco Diagnostics Inc. (BDI), the U.S. subsidiary of Bracco Imaging S.p.A., a leading global company in the diagnostic imaging business, is pleased to provide an update on its barium product portfolio as part of a comprehensive rationalization process.

 

Bracco Diagnostics Inc. launched an initiative with its barium portfolio to invest in new and expanded product offerings driven by customer and patient demand. In addition, the company is pursuing FDA approval for its fourth product and expects to file for approval later this year. Upon anticipated approval, BDI will offer an enhanced line of FDA-approved barium products for abdominal imaging needs.

 

"We remain committed to advancing the barium and oral imaging field," said Cosimo De Pinto, Senior Vice President of Sales and Marketing at BDI. "Our ongoing investment in new and expanded product offerings reflects our dedication to supporting healthcare providers in delivering exceptional patient care."

 

At the same time, market changes and evolving procedural changes have led BDI to discontinue three of its non-FDA-approved barium products due to a significant decline in product usage. BDI does not anticipate discontinuing any additional barium products.

 

"We understand the importance of providing high-quality diagnostic imaging solutions to our customers," continued Cosimo De Pinto. "Our rationalization process was essential to ensure that our resources are allocated effectively to meet the evolving needs of the medical community."

 

As part of its commitment to innovation, BDI is excited to unveil its pipeline, providing a glimpse of its upcoming product launches over the next 24 months:

 

  • Q3 2024: CitraClearTM, a gutsy filling beverage, designed to enhance patient satisfaction during preparation for imaging procedures.
  • Q4 2024: VARIBAR® (barium sulfate) “Mini” packaging, offering convenient and sustainable packaging options for healthcare facilities.
  • 2025: Introduction of a new flavor in our CT barium line, further enhancing the patient experience during imaging examinations.

 

BDI invites healthcare providers and industry partners to explore its barium pipeline and looks forward to continuing to collaborate in advancing diagnostic imaging technologies.